Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25190397 | 0.80 | THRB (0.39) | POLBKCNH3GAARAB9ASMN1; SMN2 | |
| SCHEMBL16411516 | 0.78 | SOS1 (0.58) | SOS1CNR1CNR2MAPK14GAA | |
| SCHEMBL3463415 | 0.75 | FFAR1 (0.49) | SOS1CNR1CNR2POLBCTDSP1 | |
| SCHEMBL4943208 | 0.74 | PLA2G1B (0.58) | HTTRAB9A | |
| SCHEMBL28924001 | 0.74 | SOS1 (0.63) | SOS1CNR1CNR2MAPK14TDP1 | |
| SCHEMBL16009168 | 0.74 | SOS1 (0.58) | SOS1CNR1CNR2MAPK14POLB | |
| SCHEMBL13042657 | 0.73 | RAB9A (0.59) | SOS1CNR1CNR2MAPK14POLB | |
| Hydrochloric Acid SCHEMBL10514895 | 0.72 | PLA2G1B (0.56) | KCNH3HTTRAB9A | |
| SCHEMBL24287394 | 0.71 | SOS1 (0.55) | SOS1CNR1CNR2MAPK14POLB | |
| SCHEMBL5536106 | 0.70 | SOS1 (0.54) | SOS1CNR1CNR2MAPK14GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | SOS1 1466/4885CNR1 1709/4885CNR2 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.